Nipro newsletter April 2026
Carterra 23/09/25
LB Bohle – 10.06.2025
PCI – 7th June 2024
Temax_Krautz

Current Edition

Current Edition

Integrated CDMO Services

Terumo is a global medical technology company that was founded more than 100 years ago in Japan and is now present in more than 160 countries.

Continue reading

Injectables

This is understandable when considering and analysing the numerous advantages offered by pre-fillable syringes.

Continue reading

Nasal & Pulmonary Subsection

Solstice's role is to help the pharmaceutical industry deliver on two priorities simulta-neously.

Continue reading

Advertisement

DDL 2026

Advertisement

Merxin March 2026

Advertisement

Lifecore Biomedical

Advertisement

Solstice

Advertisement

Nipro April 2026

Affiliates Want a Substantially Increased Role in Transforming Global RIM, Finds a Major New Global Study

New research has confirmed that in[1]country Life Sciences company affiliates feel unrepresented in the pursuit of streamlined regulatory information management on a global scale. In the light of this, central organisations must determine how to increase participation in efforts to improve global RIM design, to maximise efficiency for everyone and to drive a tangible return from now[1]sizeable RIM investments. Steve Gens of Gens & Associates analyses the findings.

Regulatory excellence in Life Sciences companies depends on a combination of process optimisation, effective global systems, high data quality, and enhanced affiliate collaboration. One weak link in that chain could risk compromising all the other efforts and investment. Yet, in too many cases, highly manual processes, specific local market requirements, and inconsistent use of tools have left a gap in global information visibility for pharma organisations of all sizes.

This oversight is adding risk to key regulatory processes and undermining the potential return on investment in regulatory information management systems (RIM) – the subject of extensive spending over the last 15 years across the industry. The role of affiliates, and their contribution to RIM success (or not), has been the subject of important new research we have just published at Gens & Associates. It is the most comprehensive available study performed to date, which explores the evolving role and importance of local affiliates, in efforts to make global regulatory processes more dynamic consistent and effective through optimised systems and tools. Such processes include submission forecasting and planning; product registration management; health authority interactions and commitment management; local label management; submission content management, and archiving; regulatory intelligence management; and promotional material management.

Progress is Evident, but More Work is Needed

Our latest research includes detailed feedback from 320 local offices/affiliates representing 94 countries. The affiliates represented 20 sponsor companies, most of which yielded between 10 to 25 affiliates of varying size and geographic location to participate in the research. Although this is the first time, we have investigated the affiliate perspective in such detail, we have been charting various aspects of affiliate operations in managing regulatory information as part of our World Class RIM study program for around a decade.

This has enabled us to compare the current findings with a baseline, and we have determined that companies are now roughly halfway to achieving a strong level of operating performance from a local affiliate perspective. For example, many companies are striving to reduce the time from first market to last market regulatory submission by 50% (cutting 9–12 months from this critical cycle). As things stand, 52% of the time spent by affiliates on managing their regulatory processes continues to involve use of local and regional tools, in addition to or instead of global, authoritative systems. The remaining 48% of time is now used in centrally designated platforms which is encouraging, and represents a significant improvement on the 13% reporting the same back in 2015. Clearly, there is still work to be done to further streamline operations.

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak – 21.05.2025

Advertisement

Aptar – 08/01/2026
Stoelzle – 15th May 2025
L.B. Bohle – 08.04.2025